How Olema Pharmaceuticals (OLMA) Is Adding Pipeline Depth Behind Its Palazestrant Breast Cancer Bet

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is one of the small-cap stocks with potential to rise 1000 percent. The company gave investors a new pipeline marker on May 21, when it reported initial Phase 1 clinical data for OP-3136, its KAT6 inhibitor, at the 2026 ASCO Annual Meeting. Olema said OP-3136 monotherapy was well-tolerated, with no dose-limiting toxicities observed and no discontinuations due to treatment-related adverse events, while also showing evidence of anti-tumor activity across multiple solid tumor types.

The update adds an earlier-stage asset behind Olema’s main palazestrant program, where the more immediate valuation catalyst remains OPERA-01. In its May 12 first-quarter update, Olema said topline data from the Phase 3 OPERA-01 trial of palazestrant as a monotherapy in second- and third-line ER+/HER2- metastatic breast cancer are expected in fall 2026. The company also said its Phase 3 OPERA-02 trial of palazestrant in combination with ribociclib in frontline metastatic breast cancer continued to enroll patients. Olema ended the first quarter with $505.3 million in cash, cash equivalents, and marketable securities.

Photo by National Cancer Institute on Unsplash

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA), operating as Olema Oncology, is a clinical-stage biopharmaceutical company developing targeted therapies for breast cancer and other cancers.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.